Printed From BioPortfolio.com
THE ANDA GALLOP
05:32 EST 19 Jan 2019 | PharmaBiz
In spite of several headwinds including intermittent warning letters by the US FDA even to major Indian companies, the Indian pharmaceutical companies and their subsidiaries have shown an impressive performance
Original Article: THE ANDA GALLOP
